We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Two-Step Prognostic Test Can Predict Severe COVID-19 Cases Even Before Serious Symptoms Appear

By LabMedica International staff writers
Posted on 29 Apr 2021
Print article
Illustration
Illustration
Researchers have developed a two-step prognostic test that can help predict a COVID-19 patient's response to SARS-CoV-2 infection.

The test developed by researchers at University of California (UCI; Irvine, CA, USA) combines a disease risk factor score with a test for antibodies produced early in the infection. It could be administered at the time of diagnosis to help guide therapeutic choices before the most severe symptoms appear.

Early in the pandemic, researchers developed accurate diagnostic tests and identified health conditions that correlated with worse outcomes. However, a clinical predictor of who faces the highest risk of being hospitalized, put on a ventilator or dying from the disease has remained largely out of reach. Most diagnostic tests search for antibodies associated with interrupting the virus. The UCI researchers initially set out to develop their own diagnostic, following this same strategy, but quickly realized that plenty of competing tests would soon be available. Instead, they pivoted to focus on other, unstudied antibodies - ones that wouldn't necessarily disrupt the virus or help the immune system fight the infection.

Previous studies have predicted that the SARS-CoV-2 particle has more than 55 epitopes, or sites on the virus where antibodies can attach. The best studied epitopes to date are those found on the S, or spike, protein, but the virus has three other structural proteins, each with epitopes worth investigating. Using ELISAs, or enzyme-linked immunosorbent assays, the researchers compiled a list of antibodies that might correlate with worse prognosis and ultimately focused on one that attaches to epitope 9 on the N, or nucleocapsid, protein. The group also developed a tool that used data on factors including age, sex, and pre-existing health conditions to produce a disease risk factor score (DRFS).

They tested their tool on a group of 86 people who had tested positive for the coronavirus. Patients whose tests revealed the presence of epitope 9 antibodies were more likely to have prolonged illness and worse outcomes than people without the antibodies. Of the 23 people in the study who did have the antibodies associated with epitope 9, a high DRFS predicted disease severity with more than 92% sensitivity. The test uses technology and tools readily available in testing labs. An inexpensive prognostic test could inform treatment decisions early in the disease progression. The researchers found that the epitope-9 antibodies become detectable between one and six days after the onset of symptoms.

"You can predict with really high sensitivity that someone is going to have a severe case of COVID-19," said Emily Sanders, a UCI graduate student.

Related Links:
University of California

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The BIOFIRE® SPOTFIRE® R/ST Panel has received dual 510(k) clearance and CLIA-waiver approval (Photo courtesy of bioMérieux)

Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms

The COVID-19 pandemic has demonstrated the need for healthcare professionals to have diagnostic tests available as close as possible to the patient, providing actionable results quickly.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The RedDrop One blood collection device has received 510(k) clearance from the U.S. FDA for prescription use (Photo courtesy of RedDrop Dx)

Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy

The discomfort associated with traditional blood draws leads to a significant issue: approximately 30% of diagnostic tests prescribed by physicians are never completed by patients. This avoidance is often... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.